Company Overview
Snapshot
Founded in January 2007 by Michael Marash, P-Cure is a Health Tech & Life Sciences company with 11–50 employees. The company has raised $36M across 4 funding rounds from 4 investors. In July 2022, P-Cure initiated a clinical trial in Jerusalem for its new form of proton therapy, developed in collaboration with Hadassah Medical Center.
Business overview
P-Cure develops an imaging-based solution for cost-effective cancer treatment using adaptive proton radiation. Its core technology, the P-ARTIS system, is a comprehensive and integrated solution that includes diagnostic-quality volumetric imaging, a robotic positioning system, and real-time X-ray imaging. This system enables the use of inexpensive fixed-beam technologies for treating various cancer indications, aiming to improve accuracy, expand treatment options, and shorten procedure lengths. P-Cure serves the healthcare industry, specifically targeting medical treatment and therapeutics within the medical devices sector, and is compatible with existing accelerators, beam lines, and treatment protocols.
Strategic signal
In June 2022, P-Cure announced the establishment of a new production facility in Weifang, China, spanning over 400,000 square feet. This expansion, alongside its existing Israeli facility, is crucial for meeting global market demand for its 360-degree Gantry-less Adaptive Proton Therapy System. This move signals P-Cure's strategic intent to scale production, reduce costs and lead times, and enhance global accessibility of its compact and precise proton therapy solution, positioning the company for significant market penetration in the rapidly evolving cancer treatment landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is P-Cure's primary focus?
- P-Cure focuses on developing adaptive proton therapy solutions for cancer patients, aiming to provide cost-effective and precise treatment using advanced imaging technologies.
- When did P-Cure establish its new production facility in China?
- In June 2022, P-Cure announced the establishment of a new production facility in Weifang, China, to manufacture its 360-degree Gantry-less Adaptive Proton Therapy System.
- What was a significant clinical development for P-Cure in 2022?
- In July 2022, P-Cure began a clinical trial in Jerusalem for its new proton therapy system, developed in collaboration with Hadassah Medical Center, to improve treatment accuracy and reduce toxicity.
- Which investors participated in P-Cure's February 2021 funding round?
- In February 2021, P-Cure closed a funding round with participation from Popular Line Medical Group.
- What regulatory milestone did P-Cure achieve in April 2020?
- In April 2020, P-Cure secured CE marking for its P-ARTIS System, allowing the company to market and sell its image-guided positioning system in Europe.